Novel, low cost, highly effective, handmade steroid pellets for experimental studies by Sahores, Ana et al.
Novel, Low Cost, Highly Effective, Handmade Steroid
Pellets for Experimental Studies
Ana Sahores1, Guillermina M. Luque1, Victoria Wargon1, Marı´a May1, Alfredo Molinolo2, Damasia Becu-
Villalobos1, Claudia Lanari1, Caroline A. Lamb1*
1 Institute of Experimental Biology and Medicine (IBYME), CONICET, Buenos Aires, Argentina, 2Oral and Pharyngeal Cancer Branch, National Institute of Dental and
Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America
Abstract
The basic component of SilasticH glue (Dow Corning) used to prepare SilasticH pellets is polydimethylsiloxane. This
compound is also present in other commercial adhesives such as FASTIXH (Akapol SA) that are available in any store for that
category. In the present study we developed low cost, easy to prepare handmade steroid pellets (HMSP) by mixing 17b-
estradiol, progesterone or other synthetic steroids with FASTIXH adhesive. We assessed serum levels of 17b-estradiol,
progesterone, prolactin and luteinizing hormone in ovariectomized mice treated for 24 and 48 h or 7, 14 and 28 days with
20 mg or 5 mg of 17b-estradiol or 5 mg progesterone HMSP. We found a time dependent and significant increase in the
levels of both natural hormones, and a downregulation of serum luteinizing hormone levels, while both 17b-estradiol doses
increased serum prolactin. Uterine weights at sacrifice and histological examination of the uteri and the mammary glands
correlated with estrogen or progestin action. Finally, we evaluated the biological effects of HMSP compared to commercial
pellets or daily injections in the stimulation or inhibition of hormone dependent mammary tumor growth, and found that
HMSP were as effective as the other methods of hormone administration. These data show that HMSP represent a useful,
low cost, easily accessible method for administering steroids to mice.
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Introduction
Steroid hormones play key roles in a broad range of human
physiological and pathological events [1], [2]. Rodents, mainly rats
and mice are normally used to elucidate the effects of steroids in
reproductive tissues. To avoid the cyclic influence of ovarian
hormones, rodents are usually ovariectomized and steroid
hormones replaced. Currently, different methods of delivery have
been developed such as: daily subcutaneous (sc) injections [3], [4],
sc slow-release pellets such as the ones provided by Innovative
Research of America [3], [5] and Hormone Pellet Press [6], sc
Silastic pellets [7], [8] or capsules [4], [5], [9] and, more recently,
peroral administration [5], [10]. The clearest advantage of the
pellets is that they are easily administered and do not require daily
attention, although the major drawback of most pellets is their
high cost [10]. Polydimethylsiloxane (PDMS) is a silicon-based
organic polymer present in silicone capsules and silicone adhesive
(SilasticH, Dow Corning). It has proven useful for preparing steroid
capsules or pellets, because SilasticH allows steroids to pass through
its walls, providing a means of chronic administration of the drugs
for long periods of time [8], [9] and its chemical inertness avoids
inflammatory reactions [11]. This component is also present in
other low cost, commercially available adhesives such as
FASTIXH (Akapol SA, Argentina).
The aim of the current study is to present and validate a new,
effective, low cost procedure of preparing pellets in which steroids
are mixed with a PDMS-containing adhesive. We evaluated the
effect of these handmade steroid pellets (HMSP) on serum
hormone levels, uterine weight and mammary tumor growth in
ovariectomized mice.
Materials and Methods
Animals
Female BALB/c mice (Animal facility, IByME) were fed ad
libitum and kept in air-conditioned rooms at 2062uC with a 12 h
light-dark period.
Ethics Statement
Animal care and manipulation was in agreement with
institutional guidelines, which are in accordance with the Guide
for the Care and Use of Laboratory Animals [12]. This study was
approved by the IByME Ethics Committee.
Pellet Preparation
For HMSP preparation: progesterone (Pg), 17-b-estradiol (E2),
medroxyprogesterone acetate (MPA) or mifepristone (MFP) all
from Sigma Co. (St Louis, MO, USA), were thoroughly mixed
with the PDMS-containing synthetic adhesive (FASTIXH). For Pg
5 mg we used 300 mg Pg +1.8 g FASTIXH; for E2 5 mg: 300 mg
E2+1.8 g FASTIXH; E2 20 mg: 1.3 mg E2+2.11 g FASTIXH;
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MPA 40 mg: 800 mg MPA +1.2 g FASTIXH; MFP 6 mg: 360 mg
MFP +1.8 g FASTIXH. While the adhesive was still malleable, the
mixture was pressed between two glass slides wrapped in
greaseproof paper and separated by two 6 mm spacers. The
steroid tablets were left to harden overnight at room temperature
and cut in equal pieces with a 4 mm (Pg, E2 or MFP; pellet
weight: 0.03 g) or 6 mm (MPA; pellet weight: 0.1 g) diameter
hollow punch (Balbico, Buenos Aires, Argentina). Control pellets,
with no hormone, were prepared following the same procedure
but with vehicle (FASTIXH) alone. Eventually, pellets with
different amounts of steroids can be prepared by mixing X mg
of steroid with FASTIXH, weighing the steroid tablet (Y) and
cutting and weighing 1 pellet (Z) from the tablet. Then, the
amount of steroid in each pellet is calculated using the following
formula: Steroid in 1 pellet: Z*X/Y.
Forty milligram MPA pellets were either prepared as described
above or purchased from Hormone Pellet Press (Shawnee Mission,
KS, USA).
Ovariectomy and Hormone Replacement
Ovariectomy was performed under ketamine/xylazine anesthe-
sia (10 mg/1 mg per 100 g of body weight, respectively) and,
following a one week wash-out period we implanted the HMSP
subcutaneously (sc) using a trocar into the back of 2-month-old
anesthetized mice. Mice were treated with HMSP (n = 4 per
group) containing 20 mg E2, 5 mg E2, 5 mg Pg or control for 24
or 48 hours and, 7, 14 or 28 days. Control animals (n = 13) were
implanted with vehicle-containing pellets. At each time point the
mice were weighed and blood samples and vaginal smears for
estrous cycle evaluation were collected. Animals were euthanized
by CO2 inhalation; mammary glands and uteri were dissected,
weighed, fixed in 10% buffered formalin, embedded in paraffin
and stained with hematoxylin and eosin.
Blood Sampling
Blood samples were collected under ketamine/xylazine anes-
thesia using the technique of submandibular bleeding followed by
a terminal cardiac puncture procedure. Blood samples were
allowed to clot overnight at 4uC, centrifuged at 1000 g for 5
minutes at 4uC, serum was collected and stored at 270uC until
radioimmunoassay.
Figure 1. E2, Pg, LH and Prl serum levels after E2- or Pg-HMSP implantation. Effect of E2- or Pg-HMSP on serum levels of E2 (A), Pg (B), LH
(C) or Prl (D) in ovariectomized adult mice treated for up to 28 days with the HMSP (n = 4–6/group). Values represent means 6 S.E.M. Values with
different letters are significantly different (a vs. b or a9 vs. b9: p,0.05; a vs. c or a9 vs. c9: p,0.01; and a vs. d or a9 vs. d9 or a99 vs. d99: p,0.001). Two-way
ANOVA (treatment by time) with post-hoc Fisher’s tests was performed for LH (p interaction = 0.0089), Prl (p interaction = 0.011) and E2 (p
interaction = 0.00018); and one-way ANOVA with post-hoc Fisher’s tests in Pg (p time ,0.0001). Inset: Student t test (p,0.01).
doi:10.1371/journal.pone.0064049.g001
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Tumor Growth
C4-HD is a mammary carcinoma induced by MPA in a BALB/
c female mouse. C4-HI is a hormone independent (HI) variant
derived from C4-HD, capable of growing in untreated mice and
regressing with antiprogestin treatment [13]. Both variants express
estrogen receptor alpha (ERa) and progesterone receptors (PR)
[13]. Tumors were maintained by serial sc transplantations into
MPA-treated (C4-HD) or untreated (C4-HI) female mice. To
evaluate tumor regression, when the tumors reached an approx-
imate size of 50 mm2, the animals were treated with the
antiprogestin MFP either by sc injections (solution dissolved in
phosphate buffer: 12 mg/kg/day) [14] or in the form of HMSP
(6 mg) implanted at the back of the animals. Tumor size was
measured with a caliper.
Radioimmunoassay (RIA)
All hormones were assayed by RIA. Serum E2 levels were
measured using a Double Antibody RIA kit (KE2D1– PIKE2D-9)
provided by Siemens (Siemens USA, Los Angeles, CA) following
the manufacturer’s instructions. Serum aliquots of 15 ml from the
E2 20 mg group, and 15 ml of diluted serum (1/10) from E2 5 mg
group were used in duplicate. The dilution was prepared with the
zero calibrator provided by the kit. The protocol was adapted to
280 ml of final volume, considering the amount of serum that can
be collected from one mouse, in accordance with the Guide for the
Care and Use of Laboratory Animals [12]. Calibration curve: 1–
200 pg/ml. Intra- and inter- assay coefficients of variation were
4.2 and 15.1%, respectively.
Pg was determined using an antibody provided by G. D.
Niswender, and labeled hormone (progesterone [1,2,6,7 3H(N)])
was purchased from Dupont NEN (Boston, MA) [15]. Serum
aliquots of 50 ml were used for extraction with hexane and then
500 ml of the resuspended extraction solution (2 ml) were used in
duplicate for RIA assay. The lowest detectable concentration was
12.5 pg and intra- and inter-assay coefficients of variation were 7.5
and 11.9%, respectively.
Prolactin (Prl) was measured using mouse specific reagents
provided by the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK), National Hormone and Pituitary
Program (Dr. A. F. Parlow, Torrance, CA) [16]. Assays were
performed using 10 ml of serum in duplicate. Results are expressed
in terms of mouse Prl reference preparation RP3. Intra-assay and
inter-assay coefficients of variation were 7.2 and 12.8%, respec-
tively.
Figure 2. Uterine weight and vaginal smears after E2- or Pg-HMSP implantation. (A) Ratio between uterine and total animal weight of
mice treated for 0, 24 and 48 h and 7, 14 and 28 days with E2- (20 mg), E2- (5 mg) and Pg- (5 mg) HMSP. Values with different letters are significantly
different (a vs. b: p,0.05; a vs. d or a9 vs. d9: p,0.001). (B) Percent of animals in proestrus and estrus (left) or metaestrus and diestrus (right)
following treatment with E2-HMSP (left) or Pg-HMSP (right) for different time points. *: with sustained administration of E2 pure estrus were not
observed: the smears revealed a mixture of cornified epithelial cells with leukocyte invasion probably due to the accentuation of normal physiological
changes induced by extreme hormonal stimulation [32].
doi:10.1371/journal.pone.0064049.g002
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Figure 3. Effect of E2- or Pg-HMSP in uterine and mammary gland morphology. (A) Histological features of 5- mm-thick sections of uteri
and mammary glands from mice treated for 14 days with control, E2- (20 mg), E2- (5 mg) and Pg- (5 mg) HMSP. Mice were ovariectomized followed
by a 7 day washout period and treated for 14 days. Uterus. Control: The endometrium is lined by a low cylindrical epithelium (arrow head, inset);
the endometrial stroma is densely packed (star, inset), with embedded small endometrial glands (arrow heads). The star in the main picture shows the
thinned myometrial wall. E2 20 mg: Well-developed endometrial glands with proteinaceous material inside (arrow heads). The surface epithelium is
locally stratified, composed of more than one layer of cells (arrow heads, inset). E2 5 mg: The surface epithelium is irregular and composed of one or
more cell layers (inset, white arrow head) with focal apoptosis, the lumen discloses plugs of coagulated secretion (inset, arrow head) and
mononuclear cells. Pg 5 mg: The cells lining the glandular structures are cylindrical and the nuclei are basally located (inset, arrow head). Mammary
gland. E2 20 mg: Well-developed ductal structure lined by a stratified cuboidal epithelium; a thin stromal layer is evident in this picture (arrow head).
Novel, Handmade Steroid Pellets
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LH concentrations were determined using reagents provided by
Dr. Parlow from the NIDDK [17]. Assays were performed using
75 ml of serum in duplicate. The lowest detectable concentration
was 0.015 ng. Results were expressed in terms of mouse-LH
standard (AFP 5306A). Intra- and inter-assay coefficients of
variation were less than 8 and 11%, respectively.
Uterine Epithelial Cell Height
In uterine sections endometrial epithelial cell height was
measured from the apical (luminal) surface to the basement
membrane. All measurements were made in areas where luminal
folds were not present and care was taken to avoid measuring in
sections that may have been cut obliquely. A representative section
was selected for each animal, and the average of ten measurements
per section was used in the calculations. Photographs were taken
with a Nikon Eclipse E800 Microscope and measurements were
made using Image Quant software at 400X magnification.
Immunohistochemistry
Tumor samples, mammary glands and uteri were fixed in
10% buffered formalin and embedded in paraffin. Sections were
dewaxed in xylene, rehydrated through graded ethanol, and
treated for 30 minutes with 10% H2O2 in 70u ethanol to
quench endogenous peroxidase activity. The slides were washed
extensively with distilled water followed by PBS, three times for
5 minutes each time. The sections were then incubated in 5%
albumin in PBS for 40 minutes and then reacted with PR (H-
190, rabbit polyclonal IgG, Santa Cruz Biotech, CA) or ERa
(MC-20, rabbit polyclonal IgG, Santa Cruz Biotech, CA)
diluted 1:100 in PBS for 24 h at 4uC. The slides were washed
with PBS and incubated for 60 min at room temperature with
anti-rabbit biotin-conjugated immunoglobulin (Vector Labs, San
Francisco, CA), diluted 1:250 in PBS, washed, and incubated
for 30 minutes with the ABC complex, prepared according to
the manufacturer’s directions (Vector Labs). The slides were
thoroughly washed with PBS, and developed under microscopic
control with liquid 3–39diaminobenzidine and substrate chro-
mogen system (Dako, Carpinteria, CA) following the manufac-
turer’s instructions.
Statistical Analysis
Results are expressed as means6 S.E.M. Mean hormone serum
concentration (Prl, E2 and LH) and uterine weight were analyzed
by two-way ANOVA (effects of treatment and time) and
differences among treatment groups were assessed by Fisher
protected least-significant difference (LSD) and Bonferroni post test.
One-way ANOVA was applied for serum Pg levels and means
were compared by Fisher’s LSD test. p,0.05 was considered
significant. Tumor growth curves were studied using regression
analysis and slopes compared using one-way ANOVA followed by
parallelism analysis.
Results
E2, Pg, LH and Prl Serum Levels after E2- or Pg-HMSP
Implantation
Significant levels of E2 and Pg were detected already 24 h after
pellet implantation (Figure 1A and B). High E2 levels were
maintained throughout the experiment with the 5 mg E2 pellets,
while circulating E2 values decreased from day 7 to day 14 with
the low-dose pellets, although the values were still significantly
Pg 5 mg: Ductal structure showing signs of initial lobular development (arrow heads). Magnification bar: 50 mm. (B) Effect of E2- and Pg-HMSP on
luminal epithelium height following 14 days of pellet implantation to ovariectomized mice. Bar: 10 mm. ***: p,0.001; **: p,0.01. (C) Effect of co-
administration of E2- and Pg-HMSP on luminal epithelium height following 7 days of pellet implantation to ovariectomized mice. ***: p,0.001; a vs. b:
p,0.001.
doi:10.1371/journal.pone.0064049.g003
Figure 4. ERa and PR expression in reproductive tissues.
Immunohistochemical expression of ERa (upper panel) and PR
(lower panel) in uteri (left) and mammary glands (right) treated
for 7 days with E2 (5 mg), Pg (5 mg) or vehicle alone. Bar: 50 mm.
doi:10.1371/journal.pone.0064049.g004
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Figure 5. Tumor growth and hormone receptor regulation in endocrine treated murine mammary carcinomas tumors. (A) Effects of
MPA or MFP on tumor growth. (Left) BALB/c mice were sc transplanted in the inguinal flank with C4-HD mammary carcinomas and simultaneously
MPA- (40 mg) HMSP or Hormone Pellet Press pellets were sc implanted into the back of the mice (N = 4–6/group). Treatments began when tumors
were transplanted. (Right) Mice bearing C4-HI mammary carcinomas were treated with 6 mg MFP-HMSP (N = 3), MFP solution (12 mg/kg/day; N = 3)
or left untreated (N = 6). Treatments began when tumors reached approximately 50 mm2 (arrow). Tumor sizes are expressed as mean 6 SD. (B)
Novel, Handmade Steroid Pellets
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higher than control levels even at day 28. Although both E2 curves
followed the same shape, two-way ANOVA indicated that there
was a dose-dependent effect and E2 values were lower with the low
E2 dose compared with the high E2 dose from 24 h onwards
[Figure 1A; p interaction (treatment 6 time) = 0.00018, and
p,0.0004 for E2 levels at every time point from 24 h onwards].
Circulating values of Pg showed a rapid increase at 24 h,
peaking at 48 h post pellet implant. Thereafter serum Pg levels
decreased gradually, but were still higher than controls up to 14
days (Figure 1B & inset). In the comprehensive analysis, differences
in Pg levels at day 14 were not significant probably due to the
increased variance caused by the high values measured during the
early time points, although values at least doubled those of the
control. Therefore, new trials were conducted focusing on the
detection of Pg on day 14, obtaining significantly higher levels
than in the control group (Figure 1B inset; p,0.01).
In the case of LH analysis, control serum levels were not pooled,
as in the previous analysis, because LH values changed with time
post ovariectomy and thus, low levels were found during the first
time point. Both E2 doses effectively downregulated the increase in
serum LH levels evoked by ovariectomy from days 7 to 28
(Figure 1C). On the other hand, highest Pg levels (Figure 1B) were
obtained when LH had not yet increased in response to
ovariectomy (24 and 48 h) but thereafter, Pg-HMSP-pellets
inhibited LH levels (even though not significantly at 7 days).
The degree of inhibition was lower than for E2, as expected
(Figure 1C).
It is well established that E2 enhances Prl secretion [7] and E2-
HMSP-pellets (20 mg and 5 mg) increased Prl levels, thus proving
the efficiency of these pellets. The low dose pellet induced higher
Prl levels at 24 h, 7 and 14 days, while the high-dose E2 pellet
induced Prl secretion from day 7 onwards, exerting its maximum
effect on day 14 (Figure 1D). On the other hand, Pg-HMSP did
not increase Prl levels at any time point, as expected.
Uterine Weight and Vaginal Smears after E2- or Pg-HMSP
Implantation
Uterine weight and vaginal smears were used to monitor the
pathophysiologic effects of the E2- and Pg-HMSP. Both E2 pellets
induced a significant increase in uterine weight as compared to
control- or Pg-treated animals (Figure 2A). Low doses of E2 were
sufficient to exert a maximal effect. Vaginal cornification was
observed in E2-treated mice within 48 h while Pg induced a
metestrous-diestrous state (Figure 2B). No evidences of pellet
rejection (edema or swelling) or signs of toxicity (body weight and
histopathological damage) were found at necrospy when mice
were treated with control handmade pellets (not shown).
Effect of E2- or Pg-HMSP in Uterine and Mammary Gland
Histology
The effects of E2 and Pg treatments in the uteri and mammary
glands were evident in the H&E-stained sections (Figure 3A). By
day 14, the endometrium of the untreated ovariectomized mice
was lined by a low cylindrical epithelium with scanty cytoplasm
and luminal-located nuclei; the endometrial stroma was dense,
with embedded small endometrial glands with no signs of secretion
(Figure 3A). Treatment with both doses of E2-HMSP resulted in a
tortuous endometrium lined by a tall columnar epithelium,
pseudostratification and an increase in the size and number of
glands. Endometrial glands were filled with a proteinaceous
material. In the uterine stroma, decidualization and edema was
appreciated. All these changes were typically dose-dependent
(Figure 3A). The endometrium from Pg treated mice was
composed of well-developed and convoluted glands with local
pseudopapillar images, deeply immersed in a well-vascularized
and edematous stroma (Figure 3A). The untreated mammary
glands displayed poorly developed glandular structures, lined by
cuboidal epithelium lying directly upon the adipose tissue, with
seemingly no ductal wall development. As expected, E2-treatment
induced a well-developed ductal structure lined with a stratified
cuboidal epithelium while Pg triggered lobular development
(Figure 3A).
Effect of E2- or Pg-HMSP in Uterine Luminal Epithelium
Height
Measurements of uterine luminal epithelial height following
treatments with low and high dose E2- and/or Pg-HMSP are
shown in Figures 3B and C. As expected, both E2 doses
significantly increased luminal epithelial height following 7 and
14 days of treatment. In order to test if Pg-HMSP could reduce E2
induced uterotrophy we administered Pg combined with high dose
and low dose E2 pellets during 7 days. The co-administration of
5 mg Pg-HMSP significantly reduced (although above control
levels) the effects of high and low E2 pellets (Figure 3C). Pg alone
did not affect uterine epithelial height (Figures 3B and C).
Effect of E2- or Pg-HMSP in ERa and PR Expression in the
Uteri and Mammary Glands
We examined E2 and Pg regulation of ERa and PR expression
in uteri and mammary glands by immunohistochemistry (Figure 4).
Control uteri from mice administered vehicle alone revealed
strong nuclear staining within the epithelial and stromal compart-
ment, with almost no staining in the myometrium. Treatment with
E2 resulted in a strong ERa staining within the luminal epithelial
compartment and a weak staining in the stroma. ERa staining
following 7 days of Pg treatment revealed similar results as those
obtained with control mice (Figure 4).
Immunohistochemical analysis of PR staining in uteri from
control ovariectomized mice revealed an intense staining in the
epithelial compartment while the myometrium showed almost no
staining. E2 treatment with 5 mg HMSP resulted in a strong
staining in the glandular epithelium and in the myometrium. Pg
treatment induced a marked downregulation in PR expression in
the uteri (Figure 4).
In the mammary gland, after 7 days of E2 treatment with 5 mg
HMSP, ERa expression was downregulated in the mammary
ducts while no significant changes were observed following Pg
treatment. Conversely, E2 induced while Pg downregulated PR
expression within the mammary ducts (Figure 4).
Effect of MPA- or MFP-HMSP on Mammary Tumor
Growth
Finally, we compared the effectiveness of HMSP with the
biological effect of other synthetic compounds such as the
progestin MPA and the antiprogestin MFP in an in vivo system
(Figure 5A). We found that the hormone dependent tumor (C4-
Immunohistochemical expression of ERa (right) and PR (left) in C4-HD (upper panel) and C4-HI (lower panel) mammary carcinomas. C4-HD
carcinomas were treated with MPA and when tumors reached approximately 50 mm2, the pellet was removed for 48 h in untreated tumors. C4-HI-
bearing mice were treated for 72 h with E2 (5 mg) once the tumors reached 50 mm2. Bar: 50 mm.
doi:10.1371/journal.pone.0064049.g005
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HD), which is unable to grow in the absence of the progestin [13],
grew at a similar rate with the MPA-HMSP pellets or with the
commercially available MPA pellets. Moreover, the growth of the
hormone independent tumor variant (C4-HI) which regresses after
antiprogestin treatment [18], was inhibited by MFP administered
either as HMSP (6 mg) or as sc suspension (12 mg/kg/day).
Effect of MPA- or E2-HMSP on Hormone Receptor
Regulation in Mammary Tumors
Next, we assayed the effect of MPA- and E2-HMSP on ERa
and PR expression in mammary tumors. E2 induced HI tumor
regression and, in the absence of progestin administration HD
carcinomas regressed (Figure 5B) [19], [20]. We found that MPA
treatment downregulated PR and upregulated ERa expression in
the epithelial compartment of C4-HD mammary tumors in
agreement with previous results with MPA depot [Figure 5B,
[20]]. Moreover, E2 treatment induced a strong PR staining in
carcinoma cells while downregulating ERa expression in C4-HI
mammary tumors (Figure 5B).
Discussion
In this study we demonstrate that the HMSP elaborated with
FASTIXH adhesive provides a useful method for easy delivery of
steroids to mice. These pellets combine the advantages of
administering steroids over rather long periods of time, at a low
cost and without daily attention. FASTIXH adhesive contains
PDMS, the same component present in SilasticH glue, and is easily
accessible and affordable for scientists. Moreover, no adverse
effects of FASTIXH were observed in any of the endpoints
measured in this study. This product is also sold in other countries
such as Spain and several countries in Latin America under the
same name.
We found significant levels of E2 and Pg within 24 h of initial
placement of the implant which lasted for over 28 or 14 days,
respectively. Elevated steroids resulted in an inhibition of LH
release (in E2- and Pg-treated mice), an enhanced secretion of Prl
and an increase in uterine weight (in E2-treated mice) in
accordance with the results reported by us [21] and other authors
using different techniques [7], [22], [23]. The concentration of E2
released by HMSP can be easily manipulated to obtain a
controlled delivery of the steroid. Significant E2 release was
measured throughout the experiment while Pg levels declined
substantially as already reported in other models [24], [25],
probably due to the short half-life of natural Pg [26].
The low- and high- dose E2 pellets induced a significant
increase in Prl levels within 24 h and 7 days, respectively, reaching
their maximum values at day 7 and 14, indicating a shift in the
serum Prl secretion curve depending on the E2 dose. Similar high
Prl levels were achieved by both doses. Similar to what we present
here, Bronson et al [7] reported no significant differences between
high and low E2 doses in ovariectomized mice treated for 8 days.
Furthermore, we and others have shown that very high estrogen
levels, unlike lower dosages, can inhibit or have no effect on Prl
release in mice [27], [22]. One possibility is that high estradiol
doses may interfere with the actions of hypothalamic-releasing
factors leading to storage of prolactin within the lactotrophs.
In this study we demonstrated that E2- and Pg-HMSP exerted
the expected biological effects on: vaginal smears (by inducing a
continuous estrus state), uterine weight, uterine luminal epithelial
height and ERa and PR regulation in the uteri and mammary
gland, as already reported in similar models with commercial
pellets [28], [29]. Moreover, combined administration of E2 and
Pg in ovariectomized mice reduced uterine luminal epithelial as
compared to E2 alone, being the ultimate functional proof of the
effectiveness of this delivery system.
We have previously shown that the C4-HD mammary
carcinoma grows only in progestin-treated mice while the C4-HI
tumor grows in treated or untreated mice. Both variants express
ERa and PR, and antiprogestins such as MFP induce tumor
regression [13]. In this report, we validated the effectiveness of our
HMSP by comparing the effect on HD and HI tumor growth with
commercially available sc MPA pellets or daily injections of MFP
solution, that have proven to be effective in inducing or inhibiting
tumor growth, respectively [13]. Pg HMSP induced lobular
differentiation in mammary glands from ovariectomized mice
[30], [31]. We found that HMSP induced similar biological effects
on tumor growth and mammary gland histology as the other
validated methods used to administer steroids, demonstrating that
this is an effective method for delivering steroids to mice.
In this first pharmacological phase, we have focused in
evaluating steroid release and, as a result, the well-established
effects on hormone regulation, uterine weight and histological
features in reproductive tissues. In a second phase, we will perform
experiments to try to achieve physiological endocrine profiles with
HMSP.
Conclusions
We provide clear evidence that PDMS-based adhesives such as
FASTIXH can be used to prepare highly effective and low cost
pellets. This methodology is similar to Silastic glue pellets with the
advantage that PDMS adhesives have a lower cost and can be
easily obtained in any store for that category. It is useful not only
for natural but also for synthetic steroids such as medroxyproges-
terone acetate and MFP, providing a new way to deliver steroids to
mice.
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